Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44157   clinical trials with a EudraCT protocol, of which   7327   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-000846-37
    Sponsor's Protocol Code Number:INCB18424-306
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2021-01-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2019-000846-37
    A.3Full title of the trial
    A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
    Studio di fase 3, randomizzato, in doppio cieco, controllato con veicolo, per la valutazione dell’efficacia e della sicurezza di Ruxolitinib in crema, seguito da un periodo di estensione nei partecipanti con vitiligine
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants with Vitiligo
    Studio di efficacia e sicurezza di Ruxolitinib in crema seguito da un periodo di estensione nei partecipanti con vitiligine
    A.3.2Name or abbreviated title of the trial where available
    Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
    Valutazione topica di Ruxolitinib nello studio 1 sulla vitiligine (TRuE-V1)
    A.4.1Sponsor's protocol code numberINCB18424-306
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorINCYTE CORPORATION
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIncyte Corporation
    B.5.2Functional name of contact pointClinical Trials Information
    B.5.3 Address:
    B.5.3.1Street Address1801 Augustine Cut-Off
    B.5.3.2Town/ cityWilmington
    B.5.3.3Post code19803
    B.5.3.4CountryUnited States
    B.5.5Fax number+13024252734
    B.5.6E-mailRA@incyte.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRuxolitinib Cream
    D.3.2Product code [INCB018424 PHOSPHATE CREAM 1.5%]
    D.3.4Pharmaceutical form Cream
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPCutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRUXOLITINIB
    D.3.9.1CAS number 1092939-17-7
    D.3.9.2Current sponsor codeINCB018424 phosphate
    D.3.9.3Other descriptive nameRUXOLITINIB PHOSPHATE
    D.3.9.4EV Substance CodeSUB32897
    D.3.10 Strength
    D.3.10.1Concentration unit % (W/W) percent weight/weight
    D.3.10.2Concentration typenot less then
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCream
    D.8.4Route of administration of the placeboCutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Vitiligo
    Vitiligine
    E.1.1.1Medical condition in easily understood language
    Vitiligo
    Vitiligine
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10047642
    E.1.2Term Vitiligo
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of ruxolitinib cream in participants with vitiligo.
    Valutare l’efficacia di ruxolitinib in crema nei partecipanti con vitiligine.
    E.2.2Secondary objectives of the trial
    To further assess the efficacy of ruxolitinib cream
    Secondary:
    - To evaluate the safety and tolerability of ruxolitinib cream.
    - To evaluate the ruxolitinib PK in plasma after treatment of ruxolitinib cream.
    - Valutare la sicurezza e la tollerabilità di ruxolitinib in crema.
    - Valutare ulteriormente l’efficacia di ruxolitinib in crema.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adolescents and adults aged = 12 years.
    2. Participants with a clinical diagnosis of non-segmental vitiligo with depigmented area including = 0.5% BSA on the face, = 0.5 F-VASI, = 3% BSA on nonfacial areas, = 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
    3. Participants who agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.
    4. Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child for the duration of study participation with the exception of the following:
    a. Females of non-childbearing potential (ie, or surgically sterile with a hysterectomy and/or bilateral oophorectomy OR postmenopausal, = 12 months of amenorrhea without an alternative medical cause).
    b. Prepubescent adolescents.
    Note: Information about specific types of acceptable contraceptive measures and duration of contraceptive use are provided in the protocol.
    5. Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.
    Note: Adolescents, who during the course of the study become legal adults, will be asked for their consent to continue the study, and in the
    event of lack thereof, will be discontinued from further participation.
    1. Adolescenti di età = 12 anni e adulti.
    2. Partecipanti con diagnosi clinica di vitiligine non segmentale con area depigmentata incluso = 0,5% BSA sul viso, = 0,5 F-VASI, = 3% BSA su aree non facciali, = 3 T-VASI e area totale della vitiligine corporea ( facciale e non facciale) non superiore al 10% di BSA.
    3. I partecipanti che accettano di interrompere tutti gli agenti utilizzati per il trattamento della vitiligine dallo screening durante la visita di follow-up finale di sicurezza. Sono consentiti preparati da banco ritenuti accettabili dallo sperimentatore e trucchi mimetici.
    4. I partecipanti di sesso maschile e femminile devono essere disposti ad adottare le opportune misure contraccettive per evitare la gravidanza o la nascita di un figlio per la durata della partecipazione allo studio, ad eccezione di quanto segue:
    a. Donne in età fertile (ovvero sterili chirurgicamente con isterectomia e / o ooforectomia bilaterale o postmenopausa, = 12 mesi di amenorrea senza una causa medica alternativa).
    b. Adolescenti prepubescenti.
    Nota: nel protocollo sono fornite informazioni su tipi specifici di misure contraccettive accettabili e durata dell'uso contraccettivo.
    5. Capacità di comprensione e disponibilità a firmare un ICF o consenso informato scritto del genitore (i) o tutore legale e consenso scritto del partecipante quando possibile.
    Nota: agli adolescenti, che nel corso dello studio diventano adulti, verrà chiesto il loro consenso per continuare lo studio e nel caso di sua mancanza, sarà sospeso da ulteriore partecipazione.
    E.4Principal exclusion criteria
    1. Participants who have no pigmented hair within any of the vitiligo areas on the face.
    2. Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
    3. Participants who have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
    Note: Prior use of hydroquinone is not prohibited (as it is a bleaching agent, not a depigmentation treatment).
    4. Participants with concurrent conditions and history of other diseases:
    a. Any other skin disease that, in the opinion of the investigator, would interfere with the study medication application or study assessments.
    b. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox) within 1 week before baseline.
    c. Conditions at baseline that would interfere with evaluation of vitiligo.
    d. Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
    Examples include but are not limited to the following:
    - Clinically significant or uncontrolled cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mmHg) unless approved by the medical monitor/sponsor.
    - History of thrombosis, including deep venous thrombosis and pulmonary embolism.
    - Participants with concurrent malignant disease or a history of that in the 5 years preceding the baseline visit except for adequately treated nonmetastatic malignancies.
    - Current and/or history of liver disease, including known hepatitis B or C, with hepatic or biliary abnormalities.
    - History of alcoholism or drug addiction within 1 year before screening or current alcohol or drug use that, in the opinion of the investigator, will interfere with the participant's ability to comply with the administration schedule and study assessments.
    - Participants who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
    5. Participants using any of the following treatments within the indicated washout period before baseline:
    a. 1 week: Topical drugs when used on the vitiligo areas, for example, corticosteroids, calcineurin, and phosphodiesterase type 4 inhibitors or retinoids.
    b. 4 weeks:
    - Melanocyte-stimulating agents (eg, afamelanotide).
    - Immunomodulating systemic medications (eg, corticosteroids, methotrexate, cyclosporine).
    - Any other systemic therapies that could increase the skin sensitivity to UV/visible light or impact skin pigmentation, for example, tetracyclines, metoxypsoralens.
    - Received live vaccine.
    For the full text please refer to the protocol version 2.0 dated 10 Oct 2019.
    1. Partecipanti che non hanno peli pigmentati in nessuna delle aree del viso con vitiligine.
    2. Altre forme di vitiligine (p. Es., Segmentale) o altre diagnosi differenziali di vitiligine o altri disturbi della depigmentazione della pelle (p. Es., Piebaldismo, pityriasis alba, lebbra, ipopigmentazione postinfiammatoria, ipomelanosi maculare progressiva, nevo anemico, leucoderma chimica e tinea versicolor).
    3. Partecipanti che hanno utilizzato trattamenti di depigmentazione (ad es. Monobenzone) per trattamenti precedenti di vitiligine o altre aree pigmentate.
    Nota: l'uso precedente di idrochinone non è vietato (poiché è un agente sbiancante, non un trattamento di depigmentazione).
    4. Partecipanti con condizioni concomitanti e storia di altre malattie:
    a. Qualsiasi altra malattia della pelle che, secondo il parere dello sperimentatore, interferirebbe con l'applicazione del farmaco in studio o le valutazioni dello studio.
    b. Infezione batterica, fungina o virale acuta attiva (p. Es., Herpes simplex, herpes zoster, varicella) entro 1 settimana prima del basale.
    c. Condizioni al basale che potrebbero interferire con la valutazione della vitiligine.
    d. Qualsiasi malattia grave o condizione medica, fisica o psichiatrica che, secondo l'opinione dello sperimentatore, interferirebbe con la piena partecipazione allo studio, inclusa la somministrazione del farmaco in studio e la partecipazione alle visite di studio richieste; rappresentare un rischio significativo per il partecipante; o interferire con l'interpretazione dei dati di studio.
    Gli esempi includono ma non sono limitati a quanto segue:
    - Malattia cardiaca clinicamente significativa o non controllata, inclusa angina instabile, infarto miocardico acuto entro 6 mesi dal primo giorno di somministrazione del farmaco in studio, insufficienza cardiaca congestizia di classe III o IV della New York Heart Association e aritmia che richiede terapia o ipertensione non controllata (pressione sanguigna> 150 / 90 mmHg) se non approvato dal monitor / sponsor medico.
    - Storia di trombosi, inclusa trombosi venosa profonda ed embolia polmonare.
    - Partecipanti con patologie maligne concomitanti o con anamnesi positiva nei 5 anni precedenti la visita di base, ad eccezione di tumori maligni non metastatici adeguatamente trattati.
    - Attuale e / o storia di malattia epatica, inclusa epatite B o C nota, con anomalie epatiche o biliare.
    - Storia di alcolismo o tossicodipendenza entro 1 anno prima dello screening o dell'attuale consumo di alcol o droghe che, secondo il parere dello sperimentatore, interferiranno con la capacità del partecipante di rispettare il programma di somministrazione e le valutazioni dello studio.
    - Partecipanti impegnati in un istituto in virtù di un ordine emesso dall'autorità giudiziaria o amministrativa.
    5. Partecipanti che utilizzano uno dei seguenti trattamenti entro il periodo di washout indicato prima del basale:
    a. 1 settimana: farmaci topici se usati nelle aree della vitiligine, ad esempio corticosteroidi, calcineurina e inibitori della fosfodiesterasi di tipo 4 o retinoidi.
    b. 4 settimane:
    - Agenti stimolanti i melanociti (ad es. Afamelanotide).
    - Farmaci sistemici immunomodulanti (ad es. Corticosteroidi, metotrexato, ciclosporina).
    - Qualsiasi altra terapia sistemica che possa aumentare la sensibilità della pelle ai raggi UV / luce visibile o influire sulla pigmentazione della pelle, ad esempio tetracicline, metossiporaleni.
    - Ricevuto vaccino vivo.
    Per il testo completo fare riferimento al Protocollo versione 2.0 del 10 Ottobre 2019.
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of participants achieving F-VASI75 at Week 24.
    Proporzione di partecipanti che hanno raggiunto F-VASI75 alla settimana 24.
    E.5.1.1Timepoint(s) of evaluation of this end point
    24 weeks
    24 settimane
    E.5.2Secondary end point(s)
    • Percentage change from baseline in F-BSA at Week 24.
    • Proportion of participants achieving F-VASI50 at Week 24.
    • Proportion of participants achieving F-VASI75 at Week 52.
    • Proportion of participants achieving F-VASI90 at Week 24.
    • Proportion of participants achieving F-VASI90 at Week 52.
    • Proportion of participants achieving T-VASI50 at Week 24.
    • Proportion of participants achieving T-VASI50 at Week 52.
    • Proportion of participants achieving T-VASI75 at Week 52.
    • Proportion of participants achieving a VNS of "4 – A lot less noticeable" or "5 – No longer noticeable" at Week 24.

    Secondary:
    • The frequency, duration, and severity of AEs; physical examinations; vital signs; and laboratory data for hematology and serum chemistry.
    • Proportion of participants achieving F-VASI25/50/75/90 during the treatment period (double-blind and treatment extension periods).
    • Percentage change from baseline in F-VASI during the treatment period (double-blind and treatment extension periods).
    • Percentage change from baseline in F-BSA during the treatment period (double-blind and treatment extension periods).
    • Percentage change from baseline in T-VASI during the treatment period (double-blind and treatment extension periods).
    • Percentage change from baseline in T-BSA during the treatment period (double-blind and treatment extension periods).
    • Proportion of participants achieving T-VASI25/50/75/90 during the treatment period (double-blind and treatment extension periods).
    • Proportion of participants in each category of VNS during the treatment period (double-blind and treatment extension periods).
    • Population-based (trough) plasma concentrations of ruxolitinib at Weeks 4, 24 and 40.
    • Variazione percentuale di F-BSA rispetto al basale alla Settimana 24.
    • Proporzione dei partecipanti che raggiungono F-VASI50 alla Settimana 24.
    • Proporzione dei partecipanti che raggiungono F-VASI75 alla Settimana 52.
    • Proporzione dei partecipanti che raggiungono F-VASI90 alla Settimana 24.
    • Proporzione dei partecipanti che raggiungono F-VASI90 alla Settimana 52.
    • Proporzione dei partecipanti che raggiungono T-VASI50 alla Settimana 24.
    • Proporzione dei partecipanti che raggiungono T-VASI50 alla Settimana 52.
    • Proporzione dei partecipanti che raggiungono T-VASI75 alla Settimana 52.
    • Proporzione dei partecipanti che raggiungono una VNS di “4 – Molto meno visibile” o “5 – Non più visibile” alla Settimana 24.

    Secondario:
    • La frequenza, la durata e la gravità degli eventi avversi; esami fisici; segni vitali; e dati di laboratorio per ematologia e chimica del siero.
    • Proporzione di partecipanti che hanno raggiunto F-VASI25 / 50/75/90 durante il periodo di trattamento (doppio cieco e periodi di estensione del trattamento).
    • Variazione percentuale rispetto al basale di F-VASI durante il periodo di trattamento (periodi in doppio cieco e di estensione del trattamento).
    • Variazione percentuale rispetto al basale dell'F-BSA durante il periodo di trattamento (periodi in doppio cieco e di estensione del trattamento).
    • Variazione percentuale rispetto al basale di T-VASI durante il periodo di trattamento (periodi di doppio cieco e di estensione del trattamento).
    • Variazione percentuale rispetto al basale della T-BSA durante il periodo di trattamento (periodi in doppio cieco e di estensione del trattamento).
    • Proporzione di partecipanti che hanno raggiunto T-VASI25 / 50/75/90 durante il periodo di trattamento (doppio cieco e periodi di estensione del trattamento).
    • Proporzione di partecipanti in ciascuna categoria di VNS durante il periodo di trattamento (periodi in doppio cieco e di estensione del trattamento).
    • Concentrazioni plasmatiche (di valle) basate sulla popolazione di ruxolitinib alle settimane 4, 24 e 40.
    E.5.2.1Timepoint(s) of evaluation of this end point
    4, 24 , 40 and 52 weeks
    4, 24 , 40 e 52 settimane
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    To determine the participants' quality of life.
    Determinare la qualità di vita dei pazienti
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA32
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    Bulgaria
    France
    Germany
    Italy
    Netherlands
    Poland
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 30
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 240
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state35
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 150
    F.4.2.2In the whole clinical trial 300
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Participants who successfully complete the 52-week treatment in this study may be eligible to participate in a separate extension study to evaluate durability of effect and maintenance regimens.
    I partecipanti che completano con successo lo studio di 52 settimane possono essere idonei a partecipare a uno studio di estensione separato per valutare la durata dell'effetto e i regimi di mantenimento.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-01-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-12-20
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2021-10-21
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA